
B001

Characteristics				
Age	53			
Stage at diagnosis	non-IV	2		
ECOG	1			
Metastatic organ	Lung, Liver, bone			
No. of previous lines of therapy	5			
Drugs that have been used	Anthracyclines, paclitaxel, carboplatin, vinorelbine, capecitabine, gemcitabine, tegafur and apatinib			
IHC results	AR (+, 90%), CD8 (+, 25%), FOXC1 (-)			

amplification



b B002

		-				
Character	istics					
Age	48	Baseline A ₁	nti-AR + Anti-CDK4/6	6 Anlotinib	Anlotinib	Anlotinib
Stage at diagnosis	non-IV	(2019.01)	for 2 cycles	for 1 cycles	for 3 cycles	for 4 cycles
ECOG	1	(2015)(01)	(2019.03)	(2019.04)	(2019.06)	(2019.07)
Metastatic organ	Lung					
No. of previous lines of therapy	5					
	Anthracyclines,	Lung metastasis				
	paclitaxel,					
Drugs that have been used	carboplatin, vinorelbine, gemcitabine,	-	PD	PR	SD	PD
	carboplatin, vinorelbine,	-				PD
	carboplatin, vinorelbine, gemcitabine,	-				PD

Figure S6. Patients benefited from other targets except for anti-AR plus anti-CDK 4/6 in arm B

(a) One patient with AR (+) and CD8 (+, 25%) benefited from anti-PD-1 therapy after progressed from therapy of arm B; (b) One patient with FGFR1 amplification benefited from anlotinib therapy after progressed from therapy of arm B

Abbreviations: PR, partial response; SD, stable disease; PD, progressive disease; ECOG, Eastern Cooperative Oncology Group.